Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

Core Viewpoint - Disc Medicine, Inc. is hosting a virtual KOL investor event to discuss anemia of myelofibrosis (MF) and the treatment landscape, including clinical data and development plans for its investigational drug DISC-0974 [1][2] Group 1: Event Details - The virtual event is scheduled for May 9, 2025, at 1:00 PM ET / 10:00 AM PT [1] - Presentations will include insights from leading experts on myeloproliferative neoplasms (MPNs) and the unmet need for anemia-focused treatments [2] - A live webcast will be available on Disc's Investor Relations page, with a replay accessible for 90 days [3] Group 2: DISC-0974 Overview - DISC-0974 is a monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin production and increase serum iron levels in patients with anemia of inflammation [4] - The drug was in-licensed from AbbVie in 2019 and has shown clinical proof-of-mechanism in previous trials [4] - Ongoing clinical trials include a Phase 2 trial in MF anemia and a Phase 1b/2a trial in chronic kidney disease patients [4] Group 3: Anemia of Myelofibrosis - Myelofibrosis affects an estimated 25,000 patients in the U.S., with over 80% presenting with anemia at diagnosis [6] - Hepcidin levels are approximately 12-fold elevated in MF patients, correlating with disease severity and the need for red blood cell transfusions [6] Group 4: Company Background - Disc Medicine is focused on developing novel treatments for serious hematologic diseases, targeting biological pathways related to red blood cell biology [7][8]